Profitability

Miscellaneous

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology Inc (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($1.18) by $0.06. The biopharmaceutical company earned $16.81 million during the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter in the prior year, the company earned ($1.70) EPS. View Clovis Oncology's Earnings History.

When will Clovis Oncology make its next earnings announcement?

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2018?

17 equities research analysts have issued 12-month price targets for Clovis Oncology's shares. Their predictions range from $50.00 to $125.00. On average, they anticipate Clovis Oncology's share price to reach $90.31 in the next year. View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

1. According to Zacks Investment Research, "The FDA’s accelerated approval to Clovis’ ovarian cancer treatment, Rubraca in December 2016 was a huge boost for the company. Rubraca registered slower-than- expected sales in the third quarter. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on continued approval for the drug. Rubraca is under review in EU for the same indication. Several studies evaluating Rubraca in different types of ovarian cancer patients are ongoing. Clovis is looking for label expansion in second line or later maintenance treatment for advanced ovarian cancer. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have underperformed the industry in the past year. Loss estimates have widened ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (2/21/2018)

2. JPMorgan Chase & Co. analysts commented, "2018 Procedure Growth Guidance Should Help Shares ISRG reported preliminary 4Q17 revenue of $892M (18% y/y), above our forecast of $865M and consensus’ estimates of $847M. Procedure growth of 17% came in higher than our 16.2% estimate and the Street’s 15.1% forecast. The sales breakout for 4Q included $457 in instrument revenue, $283 in system sales, and $153 for service, higher than our and Street estimates in each segment. 2018 guidance calls for 11-15% procedure growth, above our 10.9% forecast and in-line with consensus growth of 12.8%. This beat on revenue and procedure growth matched our expectations going into the report. Stellar revenue, strong procedure growth, and in-line 2018 guidance should boost shares today.   There were 216 systems shipped in the quarter, well above our 180 unit estimate and the Street’s 187. Of these, 40 were shipped under operating lease agreements. However, implied system ASPs were $1.31M, below our modeled $1.55M and a more than $200Ksequential decline from Q3." (1/11/2018)

3. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Frontier Capital Management Co. LLC, Teachers Advisors LLC, Emerald Advisers Inc. PA, Sectoral Asset Management Inc, Candriam Luxembourg S.C.A., C WorldWide Group Holding A S and Tocqueville Asset Management L.P.. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $54.93.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $2.69 billion and generates $80,000.00 in revenue each year. The biopharmaceutical company earns $-349,130,000.00 in net income (profit) each year or ($8.28) on an earnings per share basis. Clovis Oncology employs 278 workers across the globe.

MarketBeat Community Rating for Clovis Oncology (CLVS)

MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Clovis Oncology (NASDAQ:CLVS) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.